(S)-シタロプラムしゅう酸塩
(S)-シタロプラムしゅう酸塩 物理性質
- 融点 :
- 152-153°C
- 比旋光度 :
- D +12.31° (c = 1 in methanol)
- 貯蔵温度 :
- 2-8°C
- 溶解性:
- DMSO：15mg/mL以上
- 外見 :
- 粉
- 色:
- 白から黄褐色
- Merck :
- 14,2318
- BCS Class:
- 1
- 安定性：:
- 吸湿性
- InChI:
- InChI=1S/C20H21FN2O.C2H2O4/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;3-1(4)2(5)6/h4-9,12H,3,10-11,14H2,1-2H3;(H,3,4)(H,5,6)
- InChIKey:
- KTGRHKOEFSJQNS-UHFFFAOYSA-N
- SMILES:
- C1(CCCN(C)C)(C2=CC=C(F)C=C2)C2=C(C=C(C#N)C=C2)CO1.C(O)(=O)C(O)=O
- CAS データベース:
- 219861-08-2(CAS DataBase Reference)
(S)-シタロプラムしゅう酸塩 価格
もっと(15)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TOC4796 |
Escitalopram oxalate |
219861-08-2 |
10mg |
￥26000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TOC4796 |
Escitalopram oxalate |
219861-08-2 |
50mg |
￥109000 |
2024-03-01 |
購入 |
|
東京化成工業
|
E0958 |
(S)-シタロプラムしゅう酸塩 >98.0%(HPLC)(T)
(S)-Citalopram Oxalate
>98.0%(HPLC)(T) |
219861-08-2 |
200mg |
￥9200 |
2024-03-01 |
購入 |
|
東京化成工業
|
E0958 |
(S)-シタロプラムしゅう酸塩 >98.0%(HPLC)(T)
(S)-Citalopram Oxalate
>98.0%(HPLC)(T) |
219861-08-2 |
1g |
￥31600 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
E4786 |
エスシタロプラム シュウ酸塩 ≥98% (HPLC), powder
Escitalopram oxalate ≥98% (HPLC), powder |
219861-08-2 |
10mg |
￥20300 |
2024-03-01 |
購入 |
(S)-シタロプラムしゅう酸塩 化学特性,用途語,生産方法
外観
白色～ほとんど白色粉末～結晶
効能
抗うつ薬, 選択的セロトニン再取り込み阻害薬
商品名
レクサプロ (持田製薬); レクサプロ (持田製薬)
説明
Escitalopram was launched as Cipralex
? in Switzerland, Sweden and UK for
the
treatment of depression and panic disorder. It is the S-enantiomer version of the
selective serotonin reuptake inhibitor (SSRI) citalopram approved in 1989. It can be
obtained from 5cyanophthalide by successive reactions with 4-fluorophenyl magnesium
bromide and 3-(dimethylamino)propyl magnesium chloride. The resulting racemic diol can
be resolved by several routes such as crystallization with a chiral acid. Finally, a two step
cyclisation procedure affords escitalopram. Escitalopram is twice as effective as the
racemate and over 100 fold more potent than the R-enantiomer in inhibiting the 5HT
reuptake in vivo in rat brain synaptosomes. Moreover, it exhibits higher selectivity for the
human serotonin transporter relative to the noradrenaline or dopamine transporters than
any other currently available SSRl’s. In the mouse forced swim test, the duration of
immobility (which reflects antidepressant activity) for escitalopram was comparable to
citalopram and greater than (R)-citalopram. Clinical trials in patients with panic disorders or
depression have shown that escitalopram has a clinically relevant and significant effect.
Additionally, it has a faster onset of antidepressant action than citalopram. Escitalopram
has linear pharmacokinetics, with a long half-life (27-32 h). It is extensively metabolized in
the liver via cytochromes P450 to S(+)-desmethyl and S(+)-didesmethyl citalopram.
However, it has been shown to be a weak or negligible inhibitor of CYP450 drugmetabolizing
enzymes in vitro. Escitalopram is well tolerated with nausea being the most
common side effect.
化学的特性
White Solid
使用
Escitalopram oxalate may be used as a pharmaceutical primary standard for the quantification of the analyte in pharmaceutical formulations using analytical techniques.
一般的な説明
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Escitalopram Oxalate, a highly selective serotonin re-uptake inhibitor antidepressant, is a pure
S-enantiomer of the racemic, bicyclic pthalates derivatives of citalopram. It is mainly developed for the treatment of depression and anxiety disorders.
副作用
The main side effect of escitalopram include: Nausea, dry mouth, trouble sleeping, constipation, tiredness, drowsiness, dizziness, and increased sweating may occur.
(S)-シタロプラムしゅう酸塩 上流と下流の製品情報
原材料
準備製品
(S)-シタロプラムしゅう酸塩 生産企業
Global( 584)Suppliers
(S)-シタロプラムしゅう酸塩 スペクトルデータ(1HNMR)
219861-08-2((S)-シタロプラムしゅう酸塩)キーワード:
- 219861-08-2
- (S)-CITALOPRAM
- 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran-carbonitrile oxalate
- ESCITALOPRAM OXALATE
- S-(+)-CITAPROLAM OXALATE
- S-(+)-1-3-(dimethyl-amino)propyl-1-(p-fluorophenyl)-5-phthalancarbonitrileoxalate
- ESCIFALOPRAMOXALATE
- (S)-Citalopram-d6
- 1S)-1-[3-(Dimethylamino-d6)propyl]-1-(4-fluorophenyl)-1,3-dihydro -5-isobenzofurancarbonitrile
- 1S)-1-[3-(Dimethylamino-d6)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Oxalate
- Escitaloptam-d4 Oxalate
- Escitalopram for system suitability
- Escitalopram Oxalate (200 mg)
- (1S)-1-[3-(diMethylaMino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
- EscitalopraM oxalate S-(+)-CITAPROLAM OXALATE
- (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
- (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile
- CitalopraM S-IsoMer
- EscitalopraM API
- D-citalopraM oxalate
- 5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-, ethanedioate (1:1)
- S-(+)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate
- (S)-Escitalopram Oxalate
- Escitalopram oxalate, >=98%
- Escitalopram oxalate citalopram
- Citalopram Impurity 2((S)-Isomer)
- Escitalopram oxalate, 98%, a selective serotonin reuptake inhibitor
- CS-323
- [2H4]-Escitalopram Oxalate
- Escitalopram oxalate CRS
- [2H4]- (S)-Citalopram Oxalate
- (S)-シタロプラムしゅう酸塩
- (S)-1-[3-(ジメチルアミノ)プロピル]-1-(4-フルオロフェニル)-1,3-ジヒドロイソベンゾフラン-5-カルボニトリルしゅう酸塩
- エスシタロプラムしゅう酸塩
- しゅう酸(S)-シタロプラム
- エスシタロプラム シュウ酸塩
- エスシタロプラムシュウ酸塩 (JAN)